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Despite the progress in our understanding of genes 
essential for stem cell regulation and development, 
little is known about the factors secreted by stem cells 
and their effect on tissue regeneration. In particular, 
the factors secreted by human CD34+ cells remain to 
be elucidated. We have approached this challenge by 
performing a cytokine/growth factor microarray analy-
sis of secreted soluble factors in medium conditioned 
by adherent human CD34+ cells. Thirty-two abundantly 
secreted factors have been identified, all of which are 
associated with cell proliferation, survival, tissue repair, 
and wound healing. The cultured CD34+ cells expressed 
known stem cell genes such as Nanog, Oct4, Sox2, 
c-kit, and HoxB4. The conditioned medium contain-
ing the secreted factors prevented cell death in liver 
cells exposed to liver toxin in vitro via inhibition of the 
caspase-3 signaling pathway. More importantly, in vivo 
studies using animal models of liver damage demon-
strated that injection of the conditioned medium could 
repair damaged liver tissue (significant reduction in the 
necroinflammatory activity), as well as enable the ani-
mals to survive. Thus, we demonstrate that medium 
conditioned by human CD34+ cells has the potential for 
therapeutic repair of damaged tissue in vivo.
Received 3 May 2013; accepted 14 August 2013; advance online  
publication 15 October 2013. doi:10.1038/mt.2013.194
INTRODUCTION
Somatic stem cells have the capacity for self-renewal and mul-
tilineage differentiation.1–3 They reside in various tissue types 
including the bone marrow, brain, skin, muscle, pancreas, and 
liver.4 Studies have shown that soluble factors secreted within 
the tissue microenvironment including cytokines, and growth 
factors are essential in stem cell regulation and development.5–10 
They are particularly important in maintaining the homeostasis 
of their microenvironment, in addition to maintaining a crosstalk 
with surrounding stromal cells (fibroblasts, endothelial cells, and 
macrophages). Not surprisingly, emerging evidence suggests that 
cytokines can also influence stem cell fate in vitro, as well as in 
vivo.11 Although genes associated with stem cell regulation and 
development have been studied,12 the impact of cytokines and 
growth factors associated with these regulatory events is less well 
characterized.
Human CD34+ cells are the most widely studied adult stem 
cells.12,13 They reside in the bone marrow, as well as in other tissues 
and play an essential role in sustaining the formation of the blood 
and immune systems.,12,14–16 More recently, their proposed ability 
to differentiate into multiple tissue lineages has been exploited 
for the treatment of various debilitating diseases.17–20 Studies have 
shown that CD34+ cells are influenced by cytokines and growth 
factors, in addition to adhesion proteins such as integrins.21 
However, only a few studies currently show the benefit in vivo of 
factors secreted by human CD34+ cells on damaged tissue.
We have previously characterized a population of adherent 
CD34+ cells and based on morphology, flow cytometry, and gene 
expression analysis they expressed genes corresponding to lin-
eages of tissue differentiation (liver, pancreas, heart, and nerve), 
as well as hematopoiesis.18 Importantly, they also expressed stem 
cell genes including Oct4, Nanog, and Rex-1. In order to iden-
tify the factors secreted by these cells, we have approached this 
issue by performing a cytokine/growth factor microarray analysis 
of factors secreted by adherent CD34+ cells cultured in a defined 
serum-free medium. Several abundantly secreted factors were 
identified from the conditioned medium. Moreover, the condi-
tioned medium prevented cell death in cells treated with a liver 
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toxin in vitro, as well as demonstrating tissue repair properties 
in two independent animal models of liver damage. Our studies 
suggest that medium conditioned by human CD34+ cells may be 
exploited for therapeutic applications.
RESULTS
Adherent human CD34+ cells cultured in a defined 
serum-free medium
To better understand which cytokines and growth factors 
are secreted by human CD34+ cells in vitro, we have used a 
defined serum-free medium in which to grow these cells.22 A 
pure population of isolated human CD34+ cells were used for 
the studies (Figure 1a,b). Adherent human CD34+ cells were 
grown in a defined serum-free medium containing interleu-
kin (IL)-3, IL-6, and stem cell factor for 7 days as previously 
described.22 The CD34+ cells initially form small clusters that 
gradually merge into a homogenous cell population (Figure 1c). 
We found that the cells were proliferating as determined by 
the cell cycle profile (Figure 1d) and by protein expression of 
proliferation markers, Cyclin D1 and PCNA (Figure 1e). These 
data suggest that the combination of the three cytokines in the 
serum-free medium is able to sustain CD34+ cell growth and 
proliferation.
Expression of cell surface and stem cell markers
We next used flow cytometry and immunostaining approaches 
to determine whether the cells grown in the defined medium 
still expressed known cell lineage and stem cell markers. Several 
important cell surface markers including CD34, c-kit, CD45, and 
ICAM3 were expressed (Figure 2a). In addition to the cell lineage 
markers, specific stem cell markers including Oct4, HoxB4, 
Nanog, and Sox2 were expressed positively, in addition to being 
coexpressed with CD34 (Figure 2b–e). Stem cell genes such as 
Oct4, Sox2 and Nanog are essential in stem cell regulation and 
self-renewal.2 Collectively, these results suggest that the CD34+ 
cells cultured in the serum-free defined medium are able to main-
tain the expression of several important cell lineage and stem cell 
markers.
Cytokine expression profile of conditioned medium
In order to identify the secreted factors, the conditioned and 
control mediums were analyzed using a 174 cytokine antibody 
microarray chip for secreted soluble factors. Of the numerous 
factors represented on the array (Figure 3a), 32 were signifi-
cantly abundant in the conditioned medium compared with the 
control medium (Figure 3b). Some of the identified cytokines 
and growth factors such as FGF-6, IL-8, IL-10, M-CSF, GM-CSF, 
and angiopoietin-2 are important in stem cell regulation, as 
well as in cell proliferation and tissue repair.6,9,11 To gain further 
insight into how the secreted factors are interconnected with 
each other, we performed a bioinformatic analysis for protein–
protein interactions using a database called STRING (Search 
Tool for the Retrieval of Interacting Genes/Proteins).23,24 This 
database examines multiple genes and proteins simultaneously 
for physical and functional interactions based on seven differ-
ent criteria for known individual factors. Using this program, 
a predicted functional protein–protein interaction map was 
generated between the different secreted factors (Figure 3c). 
The protein–protein interaction map revealed that 17 out of 
the 32 secreted factors have some degree of multiple functional 
Figure 1  Characterization of human CD34+ cells cultured in a defined serum-free medium. (a,b) Histograms showing CD34+ cell purity. The 
x axis shows CD34-Cy5 and the y axis shows lineage cocktail antibodies (LIN) conjugated to fluorescein isothiocyanate (FITC). The LIN cocktail of 
antibodies include: CD3, CD14, CD19, CD20, CD56, CD11b, CD10, CD235a, CD7, CD8a, and CD2. Gating was determined by setting a 1% above 
the isotype control antibody to be considered positive staining. (c) Phase-contrast bright field images of 7-day–cultured adherent CD34+ cells in the 
defined serum-free medium. Representative images from four independent experiments. Bar scale, 100 µm. (d) Cell cycle profile of 7 day culturing 
of adherent CD34+ cells and K562 cells was used as a positive control. (e) Immunoblots of cyclin D1 and PCNA proliferation markers.
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Figure 2  Analysis of cell surface and stem cell markers. (a) Immunofluorescence staining for cell surface markers for CD45, CD34, ICAM3, and 
c-kit. Bar scale, 5 µm. The left panel is the antibody stain (green color) and the right panel is the DAPI stain for the nucleus (blue color). Representative 
images from three independent experiments. (b) Immunofluorescence staining for cell markers for HoxB4, Sox2, Oct4, and Nanog. Bar scale, 5 µm. 
The left panel is the antibody stain (green color) and the right panel is the DAPI stain for the nucleus (blue color). Representative images from three 
independent experiments. (c) Cytometric analysis of the cultured cells for the expression of CD45, CD34, c-kit, CD18, Oct4, Nanog, and HoxB4. 
Channel gates: FL1-H detects fluorescein isothiocyanate–conjugated antibody and FL2-H detects phycoerythrin-conjugated antibody. Gating was 
determined by setting a 1% above the isotype control antibody to be considered positive staining. Representative images from two independent 
experiments. (d) Double staining of CD34 and stem cell markers. CD34+ cells (D0) and 7 days (D7) cultured adherent CD34+ cells were stained 
with the indicated antibodies. Stem cell markers are plotted on the x axis; CD34 staining is plotted on the y axis. The percentage of double-
positive cells is shown in the upper right quadrant. (e) Colocalization of CD34 and stem cell markers on the cultured adherent CD34+ cells. DAPI, 
4′6′-diamidino-2-phenylindole.
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interactive partners. A closer analysis of these 17 factors 
for molecular and cellular functions revealed that several of 
them are important for cell proliferation, wound healing, and 
immune response (Table 1). These molecules frequently have 
overlapping activities and can act in an autocrine or paracrine 
fashion. This is not surprising because a complex network of 
growth factors and cytokines are essential for cellular differen-
tiation and tissue regeneration.
Conditioned mediumControl medium
Array map
Array 1
Array 2
Array 3
a b c d e f g h i j k l m n
1
2
3
4
5
6
7
8
9
10
1
2
3
4
5
6
7
8
9
10
1
2
3
4
5
6
7
8
9
10
a b c d e f g h i j k l m n
a b c d e f g h i j k l m n
a b c d e f g h i j k l m n
a b c d e f g h i j k l m n
a b c d e f g h i j k l m n
a
POS POS NEG NEG Blank Angiogenin BDNF BLC BMP-4 BMP-6 CK β 8–1 CNTF EGF Eotaxin
a b c d e f g h i j k l m n
a b c d e f g h i j k l m n
POS POS NEG NEG Blank Angiogenin BDNF BLC BMP-4 BMP-6 CK β 8–1 CNTF EGF Eotaxin
Eotaxin-2 Eotaxin-3 FGF-6 FGF-7 Fit-3 Ligand Fractalkine GCP-2 GDNF GM-CSF I-309 IFN-γ IGFBP-1 IGFBP-2 IGFBP-4
Eotaxin-2 Eotaxin-3 FGF-6 FGF-7 Fit-3 Ligand Fractalkine GCP-2 GDNF GM-CSF I-309 IFN-γ IGFBP-1 IGFBP-2 IGFBP-4
IGF-I IL-10 IL-13 IL-15 IL-16 IL-1α IL-1β IL-1ra IL-2 IL-3 IL-4 IL-5 IL-6 IL-7
IGF-I IL-10 IL-13 IL-15 IL-16 IL-1α IL-1β IL-1ra IL-2 IL-3 IL-4 IL-5 IL-6 IL-7
Leptin LIGHT MCP-1 MCP-2 MCP-3 MCP-4 M-CSF MDC MIG MIP-1δ MIP-3α NAP-2 NT-3 PARC
Leptin LIGHT MCP-1 MCP-2 MCP-3 MCP-4 M-CSF MDC MIG MIP-1δ MIP-3α NAP-2 NT-3 PARC
PDGF-BB RANTES SCF SDF-1 TARC TGF-β1 TGF-β3 TNF-α TNF-β Blank Blank Blank Blank POS
PDGF-BB
1
2
3
4
5
6
7
8
9
10 RANTES SCF SDF-1 TARC TGF-β1 TGF-β3 TNF-α TNF-β Blank Blank Blank Blank POS
TECK10 TIMP-1 TIMP-2 Thrombopoietin TRAIL R3 TRAIL R4 uPAR VEGF VEGF-D Blank Blank Blank Blank POS
TECK9 TIMP-1 TIMP-2 Thrombopoietin TRAIL R3 TRAIL R4 uPAR VEGF VEGF-D Blank Blank Blank Blank POS
I-TAC8 Lymphotactin MIF MIP-1α MIP-1β MIP-3β MSP-α NT-4 Osteoprotegerin Oncostatin M PIGF sgp1 30 sTNF RII sTNF-RI
I-TAC7 Lymphotactin MIF MIP-1α MIP-1β MIP-3β MSP-α NT-4 Osteoprotegerin Oncostatin M PIGF sgp1 30 sTNF RII sTNF-RI
ICAM-16 ICAM-3 IGFBP-3 IGFBP-6 IGF-I SR IL-1 R4/ST2 IL-1 RI IL-11 IL-12 p40 IL-12 p70 IL-17 IL-2 Rα IL-6 R IL-8
ICAM-15 ICAM-3 IGFBP-3 IGFBP-6 IGF-I SR IL-1 R4/ST2 IL-1 RI IL-11 IL-12 p40 IL-12 p70 IL-17 IL-2 Rα IL-6 R IL-8
CTACK4 Dtk EGF-R ENA-78 Fas/TNFRSF6 FGF-4 FGF-9 GCSF GITR-Ligand GITR GRO GRO-α HCC-4 HGF
CTACK3 Dtk EGF-R ENA-78 Fas/TNFRSF6 FGF-4 FGF-9 GCSF GITR-Ligand GITR GRO GRO-α HCC-4 HGF
POS2 POS NEG NEG Blank Acrp30 AgRP Angiopoietin-2 Amphiregulin Axl bFGF b-NGF BTC CCL-28
POS1 POS NEG NEG Blank Acrp30 AgRP Angiopoietin-2 Amphiregulin Axl bFGF b-NGF BTC CCL-28
a b c d e f g h i j k l m n
POS1 POS NEG NEG BLANK Activin A ALCAM B7-1(CD80) BMP-5 BMP-7 Cardiotrophin-1 CD14 CXCL-16 DR6 (TNFRSF21)
POS2 POS NEG NEG BLANK Activin A ALCAM B7-1(CD80) BMP-5 BMP-7 Cardiotrophin-1 CD14 CXCL-16 DR6 (TNFRSF21)
Endoglin3 Erb B3 E-Selectin Fas Ligand ICAM-2 IGF-II IL-1 R II IL-10 R β IL-13 R α2 IL-18 BP α IL-18 R β MMP-3 IL-2 R β IL-2 R γ
Endoglin4 Erb B3 E-Selectin Fas Ligand ICAM-2 IGF-II IL-1 R II IL-10 R β IL-13 R α2 IL-18 BP α IL-18 R β MMP-3 IL-2 R β IL-2 R γ
IL-21 R5 IL-5 R α IL-9 IP-10 LAP Leptin R LIF L-Selectin M-CSF R MMP-1 MMP-13 MMP-9 MPIF-1 NGF R
IL-21 R6 IL-5 R α IL-9 IP-10 LAP Leptin R LIF L-Selectin M-CSF R MMP-1 MMP-13 MMP-9 MPIF-1 NGF R
PDGF AA7 PDGF-AB PDGF R α PDGF R β PECAM-1 Prolactin SCF R SDF-1β Siglec-5 TGF-α TGF β 2 Tie-1 Tie-2 TIMP-4
PDGF AA8 PDGF-AB PDGF R α PDGF R β PECAM-1 Prolactin SCF R SDF-1β Siglec-5 TGF-α TGF β 2 Tie-1 Tie-2 TIMP-4
VE-Cadherin9 VEGF R2 VEGF R3 BLANK BLANK BLANK BLANK BLANK BLANK BLANK BLANK BLANK BLANK POS
VE-Cadherin10 VEGF R2 VEGF R3 BLANK BLANK BLANK BLANK BLANK BLANK BLANK BLANK BLANK BLANK POS
4 www.moleculartherapy.org 
© The American Society of Gene & Cell Therapy
Human CD34+ Stem Cell–conditioned Medium
Figure 3  Cytokine profiling and protein–protein interaction map. (a) A 174 cytokine and growth factor antibody array was probed with control 
medium (defined medium without cells) or concentrated (2.5-fold) conditioned medium (defined medium plus adherent CD34+ cells). The positive 
controls are located in the upper left-hand corner (four spots) and lower right-hand corner (two spots) for each membrane. The array contains dupli-
cate spots for each cytokine or growth factor. Representative images from two independent experiments. A map of the cytokines and growth factors 
are listed on the adjacent side of each array. (b) Cytokines and growth factors that had 1.5-fold or more relative to the control were scored as positive. 
A total of 32 factors were scored positive. Densitometry was used to quantify the relative intensity of the spots to the control. (c) A protein–protein 
interaction network map for the 32 secreted factors was generated using the STRING program. The STRING program covers over 2.5 million proteins. 
The confidence score was set at the highest level, >90%.
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and P value
IL-16 1.01, 0.80; 1.54, 1.20 15.79, 13.66; 12.09, 9.51
IL-1α 1.29, 1.44; 1.11, 1.97 36.61, 31.45; 40.07, 37.33
IL-1β 1.28, 2.56; 1.36, 3.19 45.2, 43.77; 40.75, 44.11
IL-5 34.11, 33.85; 33.66, 39.31 116.53, 120.04; 113.09, 122.01
IL-8 2.35, 5.65; 7.32, 3.27 162.94, 155.97; 150.99, 148.42
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LIGHT (TNFSF14) 0.77,1.06; 1.77, 1.23 51.2, 44.89; 50.72, 47.21
ENA-78 (CXCL5) 5.32, 4.98; 7.26, 9.04 90.19, 94.01; 87.29, 90.27
Amphiregulin (AREG) 2.56, 5.27; 8.24, 4.49 50.28; 48.29; 55.2, 50.71
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76.3; 3.2 × 10−5
28.1; 7.4 × 10−9
7.3; 2.7 × 10−4
7.5; 2 × 10−5
18.9; 5.9 × 10−5
23.9; 3.2 × 10−4
2.7; 2.8 × 10−5
2.5; 3.4 × 10−7
11.9; 5 × 10−10
3.4; 4 × 10−4
10.3; 3.3 × 10−9
4.9; 1.8 × 10−8
21.8; 3.8 × 10−4
28.3; 5.6 × 10−9
40.2; 5.3 × 10−5
13.6; 2.6 × 10−8
9.9; 4.9 × 10−7
3.5; 6.3 × 10−6
11.1; 9.7 × 10−9
4.1; 2 × 10−4
11.3; 8.2 × 10−9
17.8; 4.6 × 10−5
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Table 1  Molecular and cellular functions for the selected secreted factors
Symbol Name Molecular functions Cellular functions Reference
CXCL1 Chemokine (C-X-C motif) 
ligand 1
•  Chemokine activity. •   Wound healing and inflammatory  
response.
34
•  Growth activity.
•  Enzyme activation.
CXCL5 Chemokine (C-X-C motif) 
ligand 5
•  Chemokine activity. •  Potent chemotactic. 35,36
•  Wound healing.
•  Cell trafficking and differentiation.
CXCL6 Chemokine (C-X-C motif) 
ligand 6
•  Chemokine activity. •   Wound healing and inflammatory  
response.
37
PPBP (CXCL7) Proplatelet basic protein or 
Chemokine (C-X-C motif) 
ligand 6
•   Glucose transmembrane 
transporter.
•   Secretion of factors involved in tissue  
repair.
34,35
•  Chemokine activity. •  Wound healing.
•  Growth activity. •  Inflammatory response.
MIP-1α (CCL3) Chemokine (C-C motif) ligand 
3
•  Chemokine activity. •  Inflammatory response. 34,38
•  Protein kinase activity. •  Wound healing.
MIP-1β (CCL4) Chemokine (C-C motif) ligand 
4
•  Chemokine activity. •  Inflammatory response. 34,39
•  Wound healing.
•  Cell adhesion.
CCL2 (MCP1) Chemokine (C-C motif) ligand 
2
•  Chemokine activity. •  Wound healing 40
•  Protein kinase activity. •  Inflammatory response.
•  Angiogenesis.
•  Cell proliferation.
CCL22 (MDC) Chemokine (C-C motif) ligand 
22
•  Chemokine activity. •  Wound healing. 41,42
•  Inflammatory response.
•  Signal transduction.
•  Cell signaling.
CSF2 Granulocyte macrophage colony 
stimulating factor 2
•  Cytokine activity. •  Immune response. 43
•  Growth factor activity. •  Cell proliferation.
IL-1 α IL-1 α •  Cytokine activity. •  Wound healing. 44
•  Metal binding activity. •  Inflammatory response.
•  Immune response.
•  Hematopoiesis.
IL-1 β IL-1 β •  Cytokine activity. •  Wound healing. 45
•  Inflammatory response.
•  Cell differentiation.
•  Cell proliferation.
ILRN IL-1 receptor antagonist •   IL-1 receptor antagonist activity. •  Wound healing. 46
•  Cell proliferation.
•  Cell migration.
IL-5 IL-5 •  Cytokine activity. •  Immune response. 43
•  Growth factor activity.
IL-8 IL-8 •  Chemokine activity. •  Wound healing. 47,48
•  Inflammatory response.
•  Cell proliferation.
•  Cell migration.
•  Immune response.
IL-10 IL-10 • Cytokine activity. •  B cell proliferation. 49
•  Growth factor activity. •  Cell signaling.
•  Cytokine synthesis inhibition.
IL-13 IL-13 •  Cytokine activity. •  Inflammatory response. 50
•  Signal transduction.
•  Inhibits proinflammatory cytokines.
TIMP1 Tissue inhibitor of 
metallopeptidase 1
•  Growth activity. •  Wound healing. 51,52
•  Inflammatory response.
•  Cell growth and proliferation.
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Conditioned medium prevents cell death in liver cells
The information from the protein–protein interaction map lead us 
to consider the possibility that the conditioned medium may have 
protective and wound healing properties based on what is already 
known about some of the secreted factors. As it is complex and tech-
nically challenging to test all of the 32 secreted factors individually 
or in various combinations, we decided to directly test the condi-
tioned medium. We found that the conditioned medium can pre-
vent cell death in liver cells treated with a liver toxin, thioacetamide 
(TAA) (Figure 4a). We found that liver cells treated with TAA 
displayed severe structural damages, whereas TAA-treated cells 
that received the conditioned medium maintained normal struc-
tural integrity, as well as cell viability (Figure 4a,b). As it is known 
that TAA activates the caspase-3 signaling pathway,25 we tested for 
caspase-3 activity under these conditions. We observed a reduced 
level of caspase-3 activity in liver cells treated with the conditioned 
medium (Figure  4c). These results suggest that the conditioned 
medium contains secreted factors that may prevent cell death.
Conditioned medium repairs liver damage in vivo
Based on the results from the in vitro studies (Figure 4) and 
information from Table 1, we next investigated the effect of the 
conditioned medium in a rat liver model. Specifically, we used a 
clinically relevant cirrhotic rat liver model which demonstrates 
features similar to human liver cirrhosis.26 The induced cirrhotic 
rats were injected six times via tail vein with the conditioned 
medium and killed 3 days after the last injection. Important liver 
functions including aspartate aminotransferase, alanine trans-
aminase, bilirubin, and albumin were measured. We found that 
animals treated with the conditioned medium performed much 
better for all the liver functions when compared with the control 
group (Figure 5a–d). More importantly, all the animals survived 
in the treated group (Figure 6a), suggesting that the conditioned 
medium has the capacity to extend the survival outcome of the 
treated animals. To validate this observation, we specifically 
determined the amount of necroinflammatory activity in the 
damaged liver tissue. The measurement of its activity reflects 
the degree of necrosis and inflammation in the liver. The stain-
ing revealed a reduced necroinflammatory area (Figure 6b,c) 
in the treated group (15.8 ± 2.93%) compared with the control 
group (24.8 ± 4.28%). As these results suggest that the conditioned 
medium may have the capacity to repair damaged liver tissue, 
we next determined whether the cells would also have a simi-
lar affect. Surprisingly, when 7-day–cultured cells were injected 
Figure 4  Effect of the conditioned medium (CM) on damaged liver cells treated with thioacetamide (TAA). Rat liver cells with TAA displayed a 
(a) structural damage as well as (b) reduced cell viability and (c) increased caspase-3 activity as determined by ELISA assays. Error bar represent mean 
± SD (n = 3). *Student’s t-test. **Analysis of variance test (includes all the different groups). ELISA, enzyme-linked immunosorbent assay.
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into rats that were pretreated with a well-established liver toxin, 
TAA, we found improved albumin and bilirubin liver functions 
(Supplementary Figure S1).
DISCUSSION
There is a high expectation that stem cells may deliver new thera-
peutic strategies for debilitating diseases such as neurodegen-
erative conditions, diabetes, cardiovascular disorders, and liver 
disease.26 Tremendous effort has been invested in developing 
new stem cell–based therapeutic products using embryonic and 
adult stem cells for regenerative medicine. In addition to exploit-
ing stem cells themselves as the deliverable therapeutic agent, the 
idea of exploiting the factors secreted by stem cells has been less 
characterized.
The approach we have taken, using a defined serum-free 
medium to culture human CD34+ cells, has enabled the identi-
fication of several enriched secreted factors. More importantly, 
our study is the first to demonstrate that the medium conditioned 
by adherent CD34+ cells are able to reach the damaged liver and 
repair tissue in a clinically relevant liver animal model. We found 
a significant reduction in the degree of necrosis and inflammation 
(necroinflammatory activity) in the liver treated with the con-
ditioned medium, suggesting that the factors in the conditioned 
medium are capable of reducing the inflammatory response. 
We speculate that under these conditions, it is possible that the 
secreted factors in the conditioned medium may provide the nec-
essary survival and repair factors to recruit various cell types and 
to assist in the tissue repair process. In accordance with this idea, 
studies have shown that factors secreted from stem cells may be 
associated with vascular repair and regeneration.27,28 It is interest-
ing to note that many of the identified factors secreted by human 
CD34+ cells are involved in cell survival and wound healing. For 
example, the protein–protein interaction map revealed four highly 
interactive networks of chemokines (CXCL1, CXCL5, CXCL6, 
and PPBP) that belong to CXC ligand (CXCL) chemokine family, 
which is well known to recruit neutrophils to the wound site and 
actively aid in the repair process.29
The healing properties of this family have been expanded 
to  include  an  efficient  repair  and  regeneration  of  mice  liver 
with partial hepatectomy.29 There is growing evidence that this 
hepatic repair process is regulated by CXC chemokine receptor 
2 (CXCR2),30,31 which commonly binds to members of the CXCL 
chemokine family,32,33 suggesting that the four chemokines may 
play a major role in repairing injured liver cells but further studies 
are needed.
In summary, we have shown proof-of-concept that factors 
secreted by human CD34+ cells in the conditioned medium have 
tissue repair properties. If this approach proves to be successful, 
the secreted factors may be developed into a clinical product that 
could be readily processed and stored for therapeutic applications.
MATERIALS AND METHODS
Cell culture. Normal rat liver cell line CRL-1439 was obtained from 
American Type Culture Collection (Rockville, MD) and cultured in RPMI 
supplemented with 10% fetal bovine serum.
Isolation and growth of adherent CD34+ cells. Allogeneic human 
hematopoietic donor blood samples were obtained with informed patient 
consent  and  approved  by  the  Hammersmith  Hospital  Research  Ethics 
Figure 5  Effect of the conditioned medium on damaged liver tissue in vivo. (a) Alanine transaminase (ALT), (b) aspartate aminotransferase (AST), 
and (c) Bil (bilirubin) all showed reduced levels in the treated group. (d) Albumin showed slight increase level in the treated group. Statistical signifi-
cance: AST, P = 5.5 × 10−5; ALT, P = 9.2 × 10−5; Bil, P = 1.3 × 10−4; Albumin, P = 0.05. The treated and control groups contained eight rats per group.
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Committee. Samples of granulocyte-colony stimulating factor (G-CSF) 
mobilized peripheral blood progenitor cells were processed by leukapher-
esis at the Stem Cell Laboratory at the Hammersmith Hospital. Briefly, 
human mobilized peripheral blood samples were diluted in a ratio of 1:4 in 
Hanks’ buffered saline solution (Invitrogen, Paisley, UK), the mononuclear 
cells were separated by centrifugation over a Lymphoprep (Axis-Shield, 
Dundee, Scotland) density gradient at 1800 rpm for 30 minutes. The 
mononuclear cell fraction at the interface was aspirated and washed twice 
with Hanks’ buffered saline solution, and finally with magnetic cell sorting 
buffer (phosphate- buffered saline solution at pH 7.2 supplemented with 
0.5% bovine serum albumin and 2 mmol/l EDTA). CD34+ cells were iso-
lated using a CD34+ isolation kit (Miltenyi Biotec, Surrey, UK) according 
to the manufacturer’s protocol. The purity of CD34+ cells were determined 
by FACS analysis and only samples that were >95% pure were used for the 
studies. Flow cytometry analysis of isolated CD34+ cells were confirmed by 
the following antibodies: CD34-PerCP-Cy5 (1:300); lineage cocktail anti-
bodies CD3, CD14, CD19, CD20, CD56, CD11b, CD10, CD235a, CD7, 
CD8a, and CD2 conjugated to fluorescein isothiocyanate. Directly con-
jugated isotype-matched controls (1:300) (IgG1κ, IgG2a; BD Bioscience, 
Oxford, UK) were used as negative controls, while Fluorescence Minus One 
was used alternatively. Stained cells were analyzed using the BD LSRII flow 
cytometer with 488–530/30, 488–695/40, and 488–780/60 filters to view 
fluorescein isothiocyanate and PerCP-Cy5.5 respectively. At least 10,000 
cells were collected for each test sample to ensure a sufficient number of 
positive stained cells. FlowJo 7.5 software was used for the presentation of 
the results. The isolated CD34+ cells were added to 24-well or 35-mm tis-
sue-culture–treated dishes (Nunc) (Sigma-Aldrich Company, Dorset, UK) 
at a density of 2.5–5 × 105 cells in α-minimum essential medium medium 
to isolate the adherent CD34+ cells. After 30 minutes incubation, cells were 
rinsed and grown in a defined serum-free medium (CellGro; CellGenix 
GmbH, Freiburg, Germany) containing three cytokines: 250 ηg/ml of 
stem cell factor, 250 ηg/ml of IL-6, and 250 ηg/ml of IL-3 (Invitrogen or 
CellGenix GmbH) in 0.5% penicillin/streptomycin antibiotics. Cells were 
incubated at 37 °C in 5% CO2.22 Approximately 1 ml of the defined serum 
medium was added when culturing in 35-mm culture plates and 500 µl per 
well when 24-well plates were used. Total viable cells were counted using 
the trypan exclusion assay.
Cytokine expression profiling. The isolated adherent CD34+ cells (35-mm 
dishes, Nunc) (Sigma-Aldrich Company) were cultured in the defined 
serum-free medium (5 plates per array). The control dishes only contained 
the defined serum-free medium. The conditioned medium was collected 
on the 3rd and 7th days. In order to prevent any cells remaining in the con-
ditioned medium, the medium was centrifuged for 1 hour at 13,000 RPM 
at 0 °C. The conditioned media were pooled and concentrated to 2 ml using 
a Vivaspin-20 concentrator (Sigma-Aldrich Company). The concentrated 
medium (2.5-fold) was used for the RayBio human cytokine antibody array 
C-series 2000 (174 cytokines). Briefly, membranes were blocked (blocking 
buffer) followed by adding the conditioned medium or control medium. 
After 2 hours of incubation, membranes were repeatedly washed and then 
incubated with biotin-conjugated antibodies for 2 hours at room tem-
perature. The membrane was washed followed by horse-radish peroxidase 
conjugated streptavidin detection for 1 hour followed by several washes. 
The membranes were processed  followed by exposure  to hyperfilm (GE 
Healthcare, Buckinghamshire, UK). The film was processed and scanned, 
and densitometric value of each spot on the array was measured using the 
UVP GelDoc system (UVP, Cambridge, UK). Cytokines that had 1.5-fold 
or more relative to the control were scored as positive. Two independent 
experiments were performed and analyzed. Each array contained duplicate 
spots of the cytokines or growth factors. Protein–protein interaction was 
generated using the STRING (Search Tool for the Retrieval of Interacting 
Genes/Proteins) database.23,24
Immunofluorescence microscopy, flow cytometry, cell cycle, and western 
blot. To analyze the expression of cell surface and intracellular markers, flow 
cytometry and immunofluorescence analysis were performed. Approximately 
1 × 105 cells were stained and analyzed per sample. The expression of specific 
stem cell markers was performed on day-7–cultured cells. For cell surface 
markers, no permeabilization was performed before immunolabeling with 
the appropriate primary antibodies. For intracellular staining, cells were fixed 
Figure 6  Necroinflammatory activity of liver tissue treated with 
the conditioned medium. (a) Survival outcome in the treated group 
(n = 8/8) compared with the control group (n = 5/8). (b) Hematoxylin 
and eosin staining of liver tissue from the treated and control group. 
Necroinflammatory areas are indicated by black arrows. Scale bar: 100 
µm. (c) Necroinflammatory quantification. Approximately 24.8 ± 4.28% 
of the liver developed necroinflammatory activity in the control group 
versus 15.8 ± 2.93% in the treated group. Statistical significance: control 
versus the treated group, P = 0.0059.
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and permeabilized using Fix & Perm kit (Invitrogen) or 0.2% Triton-X-100 
in phosphate-buffered saline followed by labeling with appropriate primary 
antibodies. Each tube was washed and stained with the appropriate second-
ary antibody (1:500). Isotype-matched controls were used for each antigen 
stained. Analysis of the labeled cells was performed with a FACScalibur 
flow cytometer (BD Bioscience). Ten thousand cells were collected for each 
test  sample  to ensure a  sufficient number of positive  stained cells. For  the 
immunofluorescence staining, after several washes in phosphate-buffered 
saline, coverslips were mounted on glass slides with Vectashield containing 
4′6′-diamidino-2-phenylindole (Vector Laboratories, Peterborough, UK). 
Slides were visualized on a Leica DM4000 or Zeiss Axiovert 200 inverted 
fluorescence microscope. Antibodies used were anti-Nanog (1:50 and 
1:10) (Santa Cruz Biotechnology, Dallas, TX and Abcam, Cambridge, UK); 
anti-CD45 (1:200), anti-CD18 (1:100) (BD Bioscience and Abcam); anti-c-
kit (1:50 and 1:10) (BD Bioscience and Abcam); anti-CD34 (1:20 and 1:5) 
(Santa Cruz Biotechnology and Abcam); anti-ICAM3 (1:40) (Abcam); anti-
HoxB4 (1:20), anti-Sox2 (1:50 and 1:10) (Abcam and Autogen Bioclear UK, 
Wiltshire, UK); and anti-Oct-4 (1:100 and 1:15) (Sigma-Aldrich Company 
and Abcam). Appropriate isotype control antibodies were purchased from BD 
Biosciences. Gating was determined by setting a 1% above the isotype control 
antibody to be considered positive staining. For the double staining of CD34 
and stem cell markers,  the  following antibodies were used: CD34-PE-Cy5, 
c-kit-PE),  Nanog-AlexaFluor488,  Oct4-AlexaFluor488,  HoxB4-488,  Sox2-
Alexafluor488 and isotype-matched controls (IgG1κ and IgG2a,) were used 
as negative controls (BD Bioscience and Abcam). Stained cells were analyzed 
using the BD LSRII flow cytometer with 488–530/30, 488–575/26, and 488–
695/40 filters to view Alexa488, PE and PE-Cy5 respectively. For the western 
blot, all cell extracts were prepared from CD34+ cells cultured in the defined 
growth medium. CD34+ cells not cultured in the growth medium were used 
as control cells. Equal protein concentration of 60 µg were separated by SDS-
PAGE. Antibodies used were anti-CyclinD1  (1:100)  (New England Biolab, 
Ipswich); anti-PCNA (1:100) (New England Biolab); and anti-β actin (1:300) 
(Sigma-Aldrich Company). Propidium iodide staining was used to analyze 
the cell cycle and K562 cell line was used as a positive control.
In vitro TAA studies. To test the CD34+ cells cultured conditioned medium, 
rat liver cells were seeded at 2.5 × 105 on 24-well plates. After 24 hour incu-
bation, the cells were washed once with phosphate-buffered saline followed 
by α-minimum essential medium. The cells were then treated with liver 
toxin, TAA (0.2 µg/µl) (Sigma-Aldrich Company) or TAA with the condi-
tioned medium (20 µl) in α-minimum essential medium. Standard cultur-
ing medium was used a positive control. The treated cells were incubated 
for 48 hours before performing cell viability and caspase-3 assays. Cell 
viability was performed with WST-1 kit (Roche, West Sussex, UK) and the 
caspase-3 activity was determined using Caspase-3 kit (Invitrogen). Cell 
morphological analysis was determined using an Olympus microscope.
In vivo animal studies. We used a clinically relevant cirrhotic animal 
model generated from a modified diethylnitrosamine feeding protocol.26 
Briefly, male Wistar rats (150–180 g) at 7 weeks of age were obtained from 
the Animal Center of National Taiwan University. All the experiments 
were conducted in accordance with the “Guide for the Care and Use of 
Laboratory Animals” prepared by the Institutional Animal Care and Use 
Committee of National Taiwan University. The animals were given dieth-
ylnitrosamine solution daily for 11 weeks, starting with 100 ppm in the 
first week. The average body weight of the animals was measured once a 
week and the concentration of diethylnitrosamine in their drinking water 
was adjusted in proportion to the body weight each week relative to that of 
the first week. After 11 weeks, the functional liver insufficiency was deter-
mined by the decreased bile flow as previously described.26 Liver cirrhosis 
was determined by irreversible pathological change and collage accumu-
lation in the liver after 9 weeks into the induction. For the in vivo study, 
100 µl of the conditioned medium of CD34+ cells were injected via tail 
vein per cirrhotic rat in a 2-week period (a total of six injections per rat, 
eight rats per group). Control animals (n = 8) were injected with equal vol-
ume of control medium. The rats were killed 3 days after the last injection. 
Four-micrometer–thick liver sections were deparaffinized and rehydrated. 
For histological examination, the slides were stained with hematoxylin and 
eosin. Morphometric analysis was performed measuring the percentage 
of necrotic areas in 10 fields versus total section area at 200 magnification 
using the Digital Camera System HC-2500, Adobe Photoshop version 5.0J, 
and Image-Pro Plus version 3.0.1J (Media Cybernetics, Bethesda, MD).
For the in vivo study using the hepatotoxin TAA, rats were exposed to 
the TAA at 350 mg per Kg body weight, which induces liver damage. Male 
Wistar rats (Rattus norvegicus) were used in this study. Three groups were 
in the study: group 1 (n = 5, control with no TAA), group 2 (n = 7, TAA 
treated), and group 3 (n = 7, TAA treated followed by injection of cultured 
stem cells). The animals were treated with TAA for 2 consecutive days 
followed by immunosuppressant treatment (cyclosporine) at 0.5 mg/100 g 
body weight. The following day the rats were injected with 2 × 107-cul-
tured stem cells per rat. After 3 days of treatment, liver tissues and blood 
samples were taken from all the three groups for analysis. Liver func-
tions were assayed by measuring bilirubin and albumin levels (BioAssay 
Systems, Hayward, CA). Hematoxylin and eosin staining were performed 
on rat liver tissues (5 µm sections). All animal experiments were carried 
out according to the institutional and Home Office guidelines.
Statistical analysis. Statistical analyses were performed using Prism soft-
ware (version 3.0). Statistical significant differences were determined by 
Student’s t-test or one-way analysis of variance test. Data are presented as 
mean ± SDs.
SUPPLEMENTARY MATERIAL
Figure S1. Effect of the expanded CD34+ cells transplanted on dam-
aged rat liver in vivo.
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